

Contents

<i>Preface</i>	<i>iii</i>
<i>Contributors</i>	<i>x</i>

Part I: Introduction to Vaccinology

1. Vaccines and Vaccination in Historical Perspective	1
<i>Myron M. Levine and Rosanna Lagos</i>	
2. The Traditional Vaccines: An Overview	13
<i>Gordon L. Ada</i>	
3. An Overview of Biotechnology as Applied to Vaccine Development	25
<i>Graeme C. Woodrow</i>	
4. Initial Clinical Evaluation of New Vaccine Candidates: Phase 1 and 2 Clinical Trials of Safety, Immunogenicity, and Preliminary Efficacy	35
<i>Carol O. Tacket, Martha J. Mattheis, and Margaret Baker Rennels</i>	
5. Long-Term Evaluation of Vaccine Protection: Methodological Issues for Phase 3 Trials and Phase 4 Studies	47
<i>John D. Clemens, Abdollah Naficy, and Malla R. Rao</i>	
6. Economic Analyses of Vaccines and Vaccination Programs: Evaluating the Economic Rationale for Immunization	69
<i>Orin S. Levine and Benjamin Schwartz</i>	
7. Reaping the Benefits: Getting Vaccines to Those Who Need Them	79
<i>J. W. Lee, Bruce Aylward, Harry F. Hull, Amie Batson, Maureen E. Birmingham, and John Lloyd</i>	
8. Progress and Challenges in Modern Vaccinology: An Immunologist's Perspective	89
<i>Gustav J. V. Nossal</i>	
9. The Eradication of Vaccine-Preventable Diseases	93
<i>William Foege</i>	

Part II: Molecular Immunology as Applied to Vaccine Development

10. Recent Advances in Immunology: Impact on Vaccine Development	99
<i>Marcelo B. Sztein and Graham F. Mitchell</i>	
11. Computer Prediction of T-Cell Epitopes	127
<i>Anne S. De Groot, Gabriel E. Meister, James L. Cornette, Hanah Margalit, Charles DeLisi, and Jay A. Berzofsky</i>	
12. Identification of B- and T-Cell Epitopes Through Structural Characterization and Peptide Technology ..	139
<i>Juan A. Cooper and Allan J. Saul</i>	

13. The Gastrointestinal Mucosal Immune System	151
<i>Stephen P. James</i>	

Part III: Immunopotentialiation, Adjuvants, Nonliving Antigen Delivery Systems, and “Naked DNA” Vaccines

14. Adjuvants for the Future	173
<i>Robert Edelman</i>	
15. Proteosomes for Improved Nasal, Oral, or Injectable Vaccines	193
<i>George H. Lowell</i>	
16. Liposomes as Adjuvants for Vaccines	207
<i>Carl R. Alving</i>	
17. Prospects for the Development of New and Improved Vaccines Through the Use of Microencapsulation Technology	215
<i>Derek T. O'Hagan</i>	
18. Antigen Cochleate Preparations for Oral and Systemic Vaccination	229
<i>Raphael J. Mannino and Susan Gould-Fogerite</i>	
19. Ty Virus-like Particles as an Antigen Delivery System	239
<i>Guy T. Layton</i>	
20. Immunopotentiating Reconstituted Influenza Virosomal Vaccine Delivery System	247
<i>Reinhard Glück and Stanley J. Cryz, Jr.</i>	
21. Mutant Pertussis and <i>Escherichia coli</i> Heat-Labile Toxins as Adjuvants for Enhancing Local and Systemic Immune Responses to Coadministered, Nonliving Antigens	253
<i>Gillian Douce, Gordon Dougan, MariaGrazia Pizza, Rino Rappuoli, and Mark Roberts</i>	
22. Oral Vaccine Production in the Edible Tissues of Transgenic Plants	263
<i>Charles J. Arntzen and Hugh S. Mason</i>	
23. DNA-Based Vaccines: Extending the Technology	279
<i>Stephen Albert Johnston, Kathryn F. Sykes, and Michael A. Barry</i>	
24. Vaccination Against Influenza with Plasmid DNA: Cross-Strain and Homologous Protection	287
<i>John J. Donnelly, Jeffrey B. Ulmer, and Margaret A. Liu</i>	

Part IV: Live Antigen Delivery Systems

25. Vaccinia Virus as a Live Vector for Expression of Immunogens	297
<i>Charles Flexner and Bernard Moss</i>	
26. Attenuated Poliovirus as Live Vector	315
<i>Matthias Gromeier, Hui-Hua Lu, Steffen Mueller, Eckard Wimmer, and Louis Alexander</i>	
27. Attenuated <i>Salmonella</i> as a Live Vector for Expression of Foreign Antigens	331
i. Expressing Bacterial Antigens	331
<i>S. N. Chatfield and Gordon Dougan</i>	
ii. Carrying Viral Antigens	343
<i>Florian Schödel</i>	
iii. <i>Salmonella</i> Expressing Protozoal Antigens	351
<i>Myron M. Levine, James E. Galen, Marcelo B. Szein, Magda Beier, and Fernando Noriega</i>	

28. BCG as a Recombinant Vaccine Vector363
Glenn J. Fennelly, William R. Jacobs, Jr., and Barry R. Bloom
29. Attenuated *Vibrio cholerae* as a Live Vector for Expression of Foreign Antigens379
Joan R. Buterton and Stephen B. Calderwood

Part V: New and Improved Vaccines Against Diseases for Which There Already Exist Licensed Vaccines

30. New and Improved Vaccines Against Pertussis387
Erik L. Hewlett and James D. Cherry
31. New and Improved Vaccines Against Diphtheria and Tetanus417
Rino Rappuoli
32. Progress in Development of New Attenuated Strains of *Salmonella typhi* as Live Oral Vaccines Against Typhoid Fever437
Myron M. Levine, Carol O. Tacket, James E. Galen, Eileen M. Barry, S. N. Chatfield, Gordon Dougan, Fernando Noriega, and Marcelo B. Szein
33. New and Improved Vaccines Against Cholera447
- i. Attenuated *Vibrio cholerae* O1 and O139 Strains as Live Oral Cholera Vaccines447
James B. Kaper, Carol O. Tacket, and Myron M. Levine
 - ii. Oral B Subunit Killed Whole-Cell Cholera Vaccine459
Jan Holmgren, Marianne Jertborn, and Ann-Mari L. Svennerholm
34. New and Improved Vaccines Against Meningococcal Disease469
Wendell D. Zollinger
35. Epidemiological Impact of Conjugate Vaccines on Invasive Disease Caused by *Haemophilus influenzae* Type b489
Jay D. Wenger, Robert Booy, Paul T. Heath, and Richard Moxon
36. Conjugate Vaccines Against *Streptococcus pneumoniae*503
David L. Klein and Ronald W. Ellis
37. Vaccine Development for Rickettsial Infections: Rocky Mountain Spotted Fever, Epidemic Typhus, and Scrub Typhus527
Kimberly W. Schuenke and David H. Walker
38. New and Improved Vaccines Against Influenza545
Mary Lou Clements and Ina Stephens
39. New Vaccines Against Hepatitis A571
Jack T. Stapleton and Stanley M. Lemon
40. New and Improved Vaccines for Dengue, Japanese Encephalitis, and Yellow Fever Viruses587
Niranjan Kanesa-athan, Robert Putnak, and Charles H. Hoke, Jr.
41. Improved Vaccines Against Rabies607
Zhen Fang Fu, Bernhard Dietzschold, Stanley A. Plotkin, and Charles E. Rupprecht
42. Combination Vaccines for Routine Infant Immunization: Prospects, Progress, and Dilemmas619
Carole Heilman and N. Regina Rabinovich
43. New Vaccines Against Tuberculosis631
Douglas Young and Uli Fruth

44.	Live Attenuated Varicella Vaccines	647
	<i>Michiaki Takahashi and Anne A. Gershon</i>	
Part VI: Vaccines Against Diseases for Which Licensed Vaccines Have Not Previously Been Available (or Which Have Not Been Widely Licensed)		
45.	Vaccines Against Rotavirus	659
	<i>Paul A. Offit, H. Fred Clark, and Albert Z. Kapikian</i>	
46.	Experimental HIV-1 Vaccines	673
	<i>Mary Lou Clements</i>	
47.	Vaccines Against Respiratory Syncytial Virus and Parainfluenza Virus Type 3	711
	<i>James E. Crowe, Jr., Peter L. Collins, Robert M. Chanock, and Brian R. Murphy</i>	
48.	Herpes Simplex Vaccines	727
	<i>Richard J. Whitley</i>	
49.	Vaccines Against Arenaviruses and Filoviruses	749
	<i>J. Christopher S. Clegg and Anthony Sanchez</i>	
50.	Vaccines Against Papillomavirus Infections	767
	<i>Robert W. Tindle and Ian H. Frazer</i>	
51.	Vaccines Against <i>Streptococcus pyogenes</i> Infections	783
	<i>Debra E. Bessen and Vincent A. Fischetti</i>	
52.	O-Specific Polysaccharide-Protein Conjugates for Prevention of Enteric Bacterial Diseases	803
	<i>John B. Robbins, Rachel Schneerson, and Shousun C. Szu</i>	
53.	Vaccines Against Gonococcal Infection	817
	<i>Timothy A. Mietzner and Myron S. Cohen</i>	
54.	Vaccines Against <i>Shigella</i> Infections	843
	i. <i>Escherichia coli</i> - or <i>Salmonella typhi</i> -Expressing <i>Shigella</i> Antigens	843
	<i>Thomas Larry Hale and Malabi M. Venkatesan</i>	
	ii. Engineered Attenuated Mutants of <i>Shigella</i> as Live Oral Vaccines	853
	<i>Fernando Noriega, Samuel B. Formal, Karen L. Kotloff, and Alf A. Lindberg</i>	
55.	Vaccines Against Enterotoxigenic <i>Escherichia coli</i> Infections	865
	i. Oral Inactivated Vaccines Against Enterotoxigenic <i>Escherichia coli</i>	865
	<i>Ann-Mari L. Svennerholm, Christina Åhrén, and Marianne Jertborn</i>	
	ii. Live Oral Vaccines and Subunit (Purified Fimbriae and Toxin Subunit) Vaccines	875
	<i>Carol O. Tacket and Myron M. Levine</i>	
56.	Vaccines Against <i>Campylobacter jejuni</i>	885
	<i>Daniel A. Scott, Shahida Baqar, Donald H. Burr, Gary Pazzaglia, and Patricia Guerry</i>	
57.	Vaccines Against Lyme Disease	897
	<i>Robert Edelman</i>	
58.	Vaccines Against Dental Caries Infection	913
	<i>Daniel J. Smith and Martin A. Taubman</i>	
59.	Vaccines Against <i>Klebsiella</i> , <i>Pseudomonas</i> , and Septicemic <i>E. coli</i> Infections	931
	<i>Alan S. Cross and Stanely J. Cryz, Jr.</i>	
60.	Vaccines Against <i>Escherichia coli</i> and <i>Proteus</i> Urinary Tract Infections	945
	<i>Harry L. T. Mobley</i>	

61.	Vaccines Against <i>Helicobacter pylori</i>	963
	<i>Adrian Lee and Christopher Doidge</i>	
62.	Vaccines for <i>Staphylococcus aureus</i> Infections	979
	<i>Ali I. Fattom and Robert B. Naso</i>	
63.	Vaccines Against Malaria	989
i.	Synthetic Peptide Vaccines Against the Sporozoite Stage of <i>Plasmodium</i>	989
	<i>Elizabeth H. Nardin and Ruth S. Nussenzweig</i>	
ii.	Vaccines Designed to Induce Protective T-Cell Responses Against <i>Plasmodium</i> -Infected Hepatocytes	1009
	<i>John B. Sacci, Jr., Eileen D. Franke, and Stephen L. Hoffman</i>	
iii.	Spf66 Vaccine Against Asexual Erythrocytic Stages of <i>P. falciparum</i>	1027
	<i>Roberto Amador and Manuel E. Patarroyo</i>	
iv.	Vaccines Against Asexual Blood Stages of <i>Plasmodium falciparum</i>	1035
	<i>Robin F. Anders</i>	
v.	Vaccines Against Sexual-Stage Parasites of <i>P. falciparum</i> : Transmission-Blocking Vaccines	1057
	<i>David C. Kaslow</i>	
64.	Vaccines Against Leishmaniasis	1065
	<i>Carol L. Eisenberger and Charles L. Jaffe</i>	
65.	Vaccines Against Schistosomiasis	1081
	<i>Gilles J. Riveau and André Capron</i>	
 Part VII: Vaccines Against Chronic Diseases, Vaccine Therapy, and Miscellaneous Vaccines		
66.	Antitumor Vaccines	1095
	<i>Karl Erik Hellström, Ingegerd Hellström, and Lieping Chen</i>	
67.	Vaccine Therapy	1117
	<i>Donald S. Burke</i>	
68.	Vaccines to Prevent Pregnancy	1131
	<i>Vernon C. Stevens and Warren R. Jones</i>	
69.	An Anti-arthropod Vaccine: TickGARD—A Vaccine to Prevent Cattle Tick Infestations	1145
	<i>Gary S. Cobon</i>	
 Part VIII: Commercial and Regulatory Aspects of Vaccine Production and Distribution		
70.	Large-Scale Production of Live Attenuated Bacterial and Viral Vaccines	1153
	<i>Stanley J. Cryz, Jr., and Reinhard Glück</i>	
71.	Vaccine Development: The Long Road from Initial Idea to Product Licensure	1165
	<i>Jens-Peter Gregersen</i>	
72.	Inadvertant Nontarget Effects of Live Vaccines	1179
	<i>Myron M. Levine and Eileen M. Barry</i>	
73.	The Role of the Food and Drug Administration in Vaccine Testing and Licensure	1185
	<i>Bascomb F. Anthony and Ann Sutton</i>	
Index		1195